FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| <b>STATEMENT</b> | OF CHANGES | IN BENEFICIAL | <b>OWNERSHIP</b> |
|------------------|------------|---------------|------------------|

| OMB APPROVAL        |           |  |  |  |  |  |  |  |
|---------------------|-----------|--|--|--|--|--|--|--|
| OMB Number:         | 3235-0287 |  |  |  |  |  |  |  |
| Estimated average b | ourden    |  |  |  |  |  |  |  |

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Deschatelets Pascal  |   |  |   | 2. Issuer Name <b>and</b> Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [ APLS ] |  |      |   |      |  |   | (Che   | ck all applic   | tionship of Reportin<br>all applicable)<br>Director<br>Officer (give title |   | son(s) to Iss<br>10% Ov<br>Other (s                 | vner                             |                |  |  |
|--|---|--|---|---|--|------|---|------|--|---|--|---|--|---|---|----------------------------------|----------------|--|--|
| (Last) (First) (Middle) C/O APELLIS PHARMACEUTICALS, INC 100 FIFTH AVENUE  |   |  |   | 3. Date of Earliest Transaction (Month/Day/Year) 02/10/2020                               |  |      |   |      |  |   |  | X   | below)   | hief Operating  |   | below)<br>Officer                |                |  |  |
| (Street) WALTHAM MA 02451  (City) (State) (Zip)  |   |  |   | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                  |  |      |   |      |  | Line)   | ndividual or Joint/Group Filing (Check Applicable  X Form filed by One Reporting Person Form filed by More than One Reporting Person |   |  |   |   |                                  |                |  |  |
| (9)  |   |  | ,   | -Deriv  | ative  | 9 50 | curitios                                    | : Ac | nuired   | Diei  | nosed o  | of or R   | nofi   | icially   | Owned   | <u> </u>                         |                |  |  |
| Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/D   |   |  | action 2A. Deemed Execution Date,                           |   | 3. 4. Securit<br>Transaction Disposed<br>Code (Instr. 5) |      | ities Acquired (A)<br>d Of (D) (Instr. 3, 4 |      | ) or   | 5. Amou<br>Securitie<br>Benefici<br>Owned F<br>Reporter<br>Transact | int of es Fori (D) of Following d (I) (I tion(s)   |   | : Direct<br>r Indirect<br>str. 4)  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |   |                                  |                |  |  |
| Common Stock 02/10/  |   |  | /202  | 0   |  |      | A   |      | 9,375  |   | _  | \$0.00  | (Instr. 3 and 4)<br>891,118  |   |   | D                                |                |  |  |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |   |  |   |   |  |      |   |      |  |   |  |   |  |   |   |                                  |                |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)  | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | ate, Tr   | 4.<br>Transaction<br>Code (Instr.<br>8)                  |      |   |      | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |   |  | 7. Title and Amo<br>of Securities<br>Underlying<br>Derivative Secur<br>(Instr. 3 and 4) |  |   | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | tive derivative<br>ity Securitie | e<br>s<br>Illy | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|  |   |  |   | C   | ode  | v    | (A)   | (D)  | Date<br>Exercisabl   |   | expiration<br>vate   | Title   | or<br>Nui<br>of  | ount<br>mber<br>ares  |   |                                  |                |  |  |
| Stock<br>option<br>(right to   | \$44.33   | 02/10/2020                                 |   |   | A  |      | 56,250                                      |      | (2)  | 0   | 2/09/2030  | Common  | <sup>1</sup> 56  | ,250  | \$0.00  | 56,250                           | )              | D  |  |

## **Explanation of Responses:**

- 1. Consists of Shares of Common Stock issuable under 9,375 restricted stock units ("RSUs") granted pursuant to the Company's 2017 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. This RSU was granted on February 10, 2020 and will vest as to 25% of the shares underlying the RSU on the first anniversary of the grant, and 25% of the shares underlying the RSU on each anniversary of the grant thereafter through the fourth anniversary of the grant.
- 2. This option was granted on February 10, 2020 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

## Remarks:

/s/ David Watson, attorney-infact for Pascal Deschatelets

02/12/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.